Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Peet, Malcolm; Brind, Jan; Ramchand, C.N.; Shah, Saurabh; Vankar, Ganpat

doi:10.1016/s0920-9964(00)00083-9

Cited by 288 publications

(187 citation statements)

References 52 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…Controlled clinical trials in established schizophrenia indicate that either sole or augmentation therapy with omega-3 fatty acids may be beneficial (Emsley et al, 2002;Joy et al, 2006;Mellor et al, 1996;Peet et al, 2001), with some conflicting results (Emsley et al, 2006;Fenton et al, 2001;Peet and Horrobin, 2002a, b). Furthermore, controlled clinical trials in treatment-resistant depression (Nemets et al, 2002;Peet and Horrobin, 2002a, b), bipolar depression (Keck et al, 2006), bipolar affective disorder (Stoll et al, 1999), borderline personality disorder (Zanarini and Frankenburg, 2003), incarcerated young males (Gesch et al, 2002), and children with developmental coordination disorders (Richardson and Montgomery, 2005) also suggest that omega-3 fatty acids may modulate mood, impulsivity, and aggression, while potential neuroprotective effects were found in Huntington's disease (Puri et al, 2002(Puri et al, , 2005.…”

Section: Introductionmentioning

confidence: 99%

“…We speculated that E-EPA would show neuroprotective properties in vivo by maintaining neuronal integrity, protecting the brain against excitotoxicity, and support antioxidative defense. We chose E-EPA because previous controlled studies in schizophrenia have shown some benefits (Emsley et al, 2002(Emsley et al, , 2006Horrobin et al, 2002;Peet, 2003Peet, , 2001Peet and Horrobin, 2002a, b), and because treatment response has been associated with an increase in EPA (Arvindakshan et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

Berger

Wood

Wellard

et al. 2008

Neuropsychopharmacol

107

View full text Add to dashboard Cite

Ethyl-eicosapentaenoic acid (E-EPA) is an omega-3 fatty acid that has been used in a range of neuropsychiatric conditions with some benefits. However, its mechanism of action is unknown. Here, we investigate its effects on in vivo brain metabolism in first-episode psychosis (FEP). Proton magnetic resonance spectroscopy at 3 T was performed in the temporal lobes of 24 FEP patients before and after 12 weeks of treatment in the context of a larger double-blind, placebo-controlled E-EPA augmentation study. Treatment group effects for glutathione (F1,12 ¼ 6.1, p ¼ 0.03), and a hemisphere-by-group interaction for glutamine/glutamate (F1,20 ¼ 4.4, p ¼ 0.049) were found. Glutathione increased bilaterally and glutamate/glutamine increased in the left hemisphere following E-EPA administration. Improvement in negative symptoms correlated with metabolic brain changes, particularly glutathione (r ¼ À0.57). These results suggest that E-EPA augmentation alters glutathione availability and modulates the glutamine/glutamate cycle in early psychosis, with some of the metabolic brain changes being correlated with negative symptom improvement. Larger confirmatory studies of these postulated metabolic brain effects of E-EPA are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

Berger

Wood

Wellard

et al. 2008

Neuropsychopharmacol

107

View full text Add to dashboard Cite

show abstract

“…The observation that abnormalities in n-3 PUFA may play a critical role has been supported by reports of three types of essential fatty acid aberrations among schizophrenic patients [72,73]. First, several authors have reported lower concentrations of erythrocyte essential fatty acids among schizophrenic patients as compared with control subjects [72,74].…”

Section: Noreulogical Diseases -Alzheimer Dementia Depression Attenmentioning

confidence: 88%

Alteration of polyunsaturated fatty acid status and metabolism in health and disease

Zamaria¹

2004

Reprod. Nutr. Dev.

120

View full text Add to dashboard Cite

-Essential polyunsaturated fatty acids (PUFA) cannot be synthesised in the body and must be ingested by food. A balanced intake of both n-6 and n-3 PUFA is essential for good health. PUFA are the basic constituents of phospholipid membranes and determine cellular membrane fluidity and modulate enzyme activities, carriers and membrane receptors. They are also precursors of active metabolites known collectively as eicosanoids (prostaglandins, prostacyclins, thromboxanes and leukotrienes) which regulate our cellular functions. Studies indicate that n-3 PUFA have anti-inflammatory, antithrombotic, antiarrhythmic actions and immuno-modulating properties. Erythrocyte fatty acid status is a reflection of dietary fat intake. It also explores PUFA metabolism and gives information about the integration of these fatty acids into cellular membranes. Thus, erythrocyte fatty acid analysis can detect PUFA insufficiencies and imbalances from the diet, but also metabolic abnormalities and lipid peroxidation. It can be helpful in the prevention and the control of chronic diseases in which PUFA alterations have been observed as coronary heart diseases, hypertension, cancer, diabetes, inflammatory and auto-immune disorders, atopic eczema, Alzheimer dementia, major depression, schizophrenia, multiple sclerosis, etc.essential fatty acids / erythrocytes / metabolism / chronic diseases

show abstract

“…A case study is used to illustrate the economics of recovery of eicosapentaenoic acid (EPA), an essential fatty acid from microalgae. EPA is an established neutraceutical and evidence is emerging for its therapeutic benefits in disease management (Peet et al, 2001(Peet et al, , 2002.…”

Section: Introductionmentioning

confidence: 99%

Recovery of microalgal biomass and metabolites: process options and economics

Grima

Belarbi

Fernández

et al. 2003

Biotechnology Advances

1,892

705

View full text Add to dashboard Cite

Commercial production of intracellular microalgal metabolites requires the following: (1) largescale monoseptic production of the appropriate microalgal biomass; (2) recovery of the biomass from a relatively dilute broth; (3) extraction of the metabolite from the biomass; and (4) purification of the crude extract. This review examines the options available for recovery of the biomass and the intracellular metabolites from the biomass. Economics of monoseptic production of microalgae in photobioreactors and the downstream recovery of metabolites are discussed using eicosapentaenoic acid (EPA) recovery as a representative case study. D

show abstract

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Cited by 288 publications

References 52 publications

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

Alteration of polyunsaturated fatty acid status and metabolism in health and disease

Recovery of microalgal biomass and metabolites: process options and economics

Contact Info

Product

Resources

About